title: Mass trial of hypoallergenic rice (HRS-1) produced by enzymatic digestion in atopic dermatitis with suspected rice allergy. HRS-1 Research Group.
abstract: The clinical usefulness of a hypoallergenic rice (HRS-1) which was produced by enzymatic decomposition of the constituent proteins of original rice was evaluated in a multicentre study in 44 subjects with recalcitrant atopic dermatitis (AD), who were suspected of having rice allergy. The subjects were fed for at least 4 weeks with HRS-1 instead of eliminating both regular rice and wheat from their daily diet. The extent of overall skin lesions was expressed by using the AD affected area and severity index (ADASI). A statistically significant decrease in ADASI was observed at the 2nd and the 4th week readings and at the end of the study. A provocation test with regular rice was carried out in 5 of 44 subjects following the HRS-1 therapy. An obvious increase in ADASI was found in all of these 5 cases just after this procedure. On final evaluation, 77% of the patients tested showed 'moderate' to 'remarkable' improvement, and 59% of the patients a 'moderate' to 'remarkable' reduction in use of the steroid ointment concomitantly used for the treatment. Finally, HRS-1 was evaluated as 'useful' or 'very useful' in 69% of the subjects.
authors: Dept. Dermatol., Yokohama City Univ. School of Med., Japan.
authors: Z
authors: Z
authors: Ikezawa
authors: T
authors: T
authors: Ikebe
authors: H
authors: H
authors: Ogura
authors: H
authors: H
authors: Odajima
authors: F
authors: F
authors: Kurosaka
authors: H
authors: H
authors: Komatu
authors: K
authors: K
authors: Sase
authors: C
authors: C
authors: Suga
authors: M
authors: M
authors: Sugiuchi
authors: H
authors: H
authors: Suguro
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000178:diet therapy* / Q000209:etiology*; D005260:Female; D005512:Food Hypersensitivity / Q000178:diet therapy*; D006801:Humans; D007223:Infant; D008297:Male; D012275:Oryza / Q000009:adverse effects* / Q000276:immunology